The annual mammogram is presented as an act of personal responsibility — a woman taking charge of her health. Question it and you are immediately positioned as someone who doesn't care about breast cancer. This framing has been effective. It has also prevented an honest conversation about what the evidence actually shows.

Mammography screening is a real medical intervention with real tradeoffs. It detects some cancers early enough to make a meaningful difference. It also generates enormous numbers of false-positive findings, leads to biopsy and treatment for cancers that would never have caused harm, and carries its own radiation exposure risk that accumulates over decades of screening. These are not anti-science claims — they are the documented findings of peer-reviewed research published in the journals that medicine considers authoritative.

The question is not whether mammography has any value. The question is whether women are given the full picture — including the downsides — in a way that allows them to make a genuine informed decision. In most clinical settings, they are not.

of women screened annually for 10 years will get at least one false-positive result

of breast cancers detected by screening are estimated to be overdiagnosed — meaning they would never have caused harm

of screened women will undergo an unnecessary biopsy over 10 years of annual mammography

of women have dense breast tissue — in whom mammograms are significantly less effective, but who are rarely told this at the point of screening

These numbers come from the same mainstream medical literature that drives screening guidelines. The Nordic Cochrane Centre, after conducting the most comprehensive review of mammography randomized controlled trials, concluded that for every woman whose life is saved by mammography screening, ten women are overdiagnosed and treated unnecessarily. The authors — whose work has been published and replicated across multiple research groups — found that the mortality reduction benefit from mammography is smaller than originally estimated, and the harm from overdiagnosis and overtreatment is larger.

Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews. 2013;6:CD001877. (Nordic Cochrane Centre systematic review)

Welch HG, Black WC. Overdiagnosis in Cancer. JNCI. 2010;102(9):605–613. Estimated 1.3 million women overdiagnosed in the US over 30 years of screening.

A false positive is not a minor inconvenience. When a woman is "recalled" after a mammogram — told that the imaging found something that needs to be looked at more closely — the psychological impact is immediate and documented. Anxiety, fear, disrupted sleep, and a period of living under the assumption that you may have cancer are the standard experience. That experience has real physiological effects: cortisol dysregulation, immune suppression, sleep disruption. These effects persist beyond the point when the all-clear is given, and they do not appear in the cost-benefit columns of screening guidelines.

The downstream consequences are also documented. Women who receive false-positive results that require additional imaging or biopsy are significantly less likely to return for future screening — meaning the false positive does real harm to future health behavior. And the biopsy itself — a needle or surgical procedure performed on the basis of a finding that turned out to be benign — carries its own risks, including infection, hematoma, and scarring.

Overdiagnosis occurs when screening detects a cancer — a real cancer, confirmed by biopsy — that would never have gone on to cause symptoms, spread, or death. The cancer is biological fact; the harm comes from the treatment, not the cancer. In the context of breast screening, this is not a theoretical concern. It is a documented reality that has been the subject of a decades-long scientific debate that has never resolved because there is no way, at the individual level, to know which cancers would have remained dormant.

Ductal Carcinoma In Situ (DCIS) is the diagnosis at the center of this conversation. DCIS — cancer cells confined to the milk ducts, not yet invasive — is now diagnosed in approximately 60,000 American women per year as a result of mammography screening. Historically, it was treated aggressively: mastectomy, lumpectomy with radiation, hormone suppression. Long-term follow-up studies have since demonstrated that a significant proportion of DCIS cases, if left untreated, would never have progressed to invasive breast cancer. Women who underwent mastectomy for DCIS had the same long-term breast cancer mortality as women who had lumpectomy — suggesting that for many of these cases, the extent of treatment made no survival difference.

— Dr. H. Gilbert Welch, Professor of Medicine, Dartmouth Institute for Health Policy

The harm of overdiagnosis is not theoretical — it is the cumulative burden of chemotherapy, radiation, hormonal suppression, and surgery administered to women who did not need it. These treatments carry real risks: radiation-induced heart disease and secondary cancers, chemotherapy-associated cognitive impairment ("chemo brain"), hormonal suppression side effects, and surgical complications. Women who were treated aggressively for cancers that would have remained dormant bear the long-term burden of those treatments for the rest of their lives.

Narod SA, et al. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncology. 2015;1(7):888–896. 20-year mortality data on DCIS; mortality did not differ based on treatment modality, raising questions about aggressive intervention.

Video Transcript

Estimated runtime: ~4:00–4:30

Video in Production

This video is currently being filmed. The full transcript is below.

I want to talk about a pattern I've seen consistently in women with breast cancer — and I'm talking about a lot of women over a lot of years. Not in every case. But often enough that it became something I watch for.

It's not one substance. It's the long-term concurrent use of several everyday things — each one considered safe in isolation — whose combined estrogenic, inflammatory, and immune-suppressive burden accumulates over years on tissue that is estrogen-sensitive.

Here's what that pattern can look like. Chronic high caffeine intake — which in some studies stimulates proliferation of estrogen-sensitive breast tissue and alters sleep architecture and cortisol rhythm. Diphenhydramine, sold as Benadryl and in most sleep aids — anticholinergic, associated with increased breast cancer risk in long-term OTC use in a 2019 University of Washington study, and it disrupts the sleep cycles that allow melatonin to do its tumor-suppressive work.

Corticosteroid inhalers — the kind prescribed for asthma and allergies — with chronic use, create systemic immune suppression and suppress the cortisol axis; some research links long-term inhaled steroid use to elevated breast cancer risk. Cetirizine — Zyrtec — where emerging research suggests that antihistamines may block histamine's anti-tumor immune signaling in some cancers. Chronic NSAID use — which damages gut lining, alters microbiome composition, disrupts prostaglandin balance, and creates kidney burden that compounds hormonal clearance issues.